Combination of LIVERfASt (LF) & Liver Stiffness Measurement (LSM) in patients with type 2 diabetes (T2D)
Combining LIVERFASt with Liver Stiffness Measurement (LSM) is more effective than FIB-4 & LSM for identifying advanced liver fibrosis in […]
LIVERFASt: Non-Invasive Liver Assessment for Chronic Hepatitis B & Diabetes
This publication introduces LIVERFASt, a non-invasive biomarker for predicting liver steatosis and fibrosis in patients with chronic Hepatitis B and
Fatty Liver Explained: Causes, Prevention, and Early Detection
What Is Fatty Liver Disease? Fatty liver disease, now widely known as MASLD (Metabolic dysfunction-associated steatotic liver disease), is a
Fibronostics to Exhibit at THASL 2025 Annual Conference in Bangkok
Fibronostics is pleased to announce its participation in the THASL 2025 Annual Conference, hosted by the Thai Association for the Study of the
Fibronostics Achieves SOC 2 Compliance
Fibronostics is now officially SOC 2 Type II compliant! This compliance reflects our deep commitment to keeping your data and
Why Early Liver Health Monitoring Matters?
When it comes to liver disease, early intervention isn’t just helpful, it’s critical. Known as the body’s “silent organ,” the
Overlap Between Liver Disease and Inflammatory Bowel Disease
Inflammatory Bowel Disease (IBD), which includes Crohn’s disease and ulcerative colitis, is primarily known for affecting the gastrointestinal tract. However,
Silent Link Between Hypertension and Liver Disease
High blood pressure doesn’t just strain your heart – it may quietly damage your liver too. Several studies, including a
Fibronostics is ISO27001:2022 Certified Yet Again in 2025
We did it again! Fibronostics is proud to announce that we have successfully renewed our ISO 27001:2022 certification for
Understanding the Progression of Liver Disease
Liver disease often progresses silently, with early stages showing minimal or no symptoms. However, the encouraging news is that these